IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
2.03
2.03
Rango anual
0.44
3.03
Cambio diario
-8.97%
Variación mensual
-6.88%
Variación en los últimos 6 meses
-9.38%
Cambio anual
+314.29%
Cierres anteriores
2.2 3
Open
2.0 3
Mínimo
2.0 3
Máximo
2.0 3
Volumen
34
Ver el calendario completo

Financials

Visión general Informes Estadísticas Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q4 FY2025

Full document

Century Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC), an emerging growth company, on December 9, 2025. The report details corporate governance changes effective as of the filing date.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on board appointments and related compensation arrangements.

Material Changes

The Board of Directors increased its size from six to eight members. Two new independent directors were appointed:

  • Dr. Martin Murphy: Appointed as a Class III director (term expires 2027). He will serve on the Compensation and Nominating and Corporate Governance Committees. His background includes roles at Synairgen plc, Cora Biosciences Limited, and previously as CEO of Syncona Investment Management Limited.
  • Dr. Han Lee: Appointed as a Class II director (term expires 2026). He will serve on the Compensation and Audit Committees. His background includes serving as CFO for ImmPACT Bio, Neogene Therapeutics, and Arcellx, Inc.

Compensation and Governance Details

Both directors are compensated under the Company's Non-Employee Director Compensation Policy:

  • Equity: Each received an initial option award to purchase 88,000 shares of common stock, vesting in equal monthly installments over 36 months.
  • Cash Retainer: Each is entitled to an annual cash retainer of $40,000.
  • Independence: The Board determined both individuals are independent under Nasdaq listing rules. No material related-party transactions were disclosed.

Investor Verification Checklist

  • Verify the vesting schedule and exercise price of the 88,000 share option grants for Dr. Murphy and Dr. Lee.
  • Confirm the updated Board composition and committee assignments on the Company's investor relations website.
  • Review the attached Press Release (Exhibit 99.1) for additional strategic context regarding the appointments.
  • Monitor future filings for any changes to the Company's capital structure resulting from the equity grants.

Noticias